Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Masatoshi Kudo

doi:10.1159/000540801

Related publications

Editorial Material2022

Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Masatoshi Kudo

Article2025

Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis

Masatoshi Kudo, Atsushi Hiraoka, Kazushi Numata, Tatsuya Yamashita, Masayuki Kurosaki, Tadashi Namisaki, Shuhei Hige, Yoshito Itoh, Satoshi Mochida, Tetsuya Hosaka, Norio Akuta, Tomokazu Kawaoka, Takuya Genda, Satoshi Kobayashi, Sawako Uchida‐Kobayashi, Yuting Lu, T Ogata, Maria Jesus Jimenez Exposito, Masafumi Ikeda

Article2024

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.

Peter R. Galle, Thomas Decaens, Masatoshi Kudo, Shukui Qin, Leonardo Goliatt, Bruno Sangro, Hatim Karachiwala, Joong‐Won Park, Edward Gane, Matthias Pinter, David Tai, Armando Santoro, Gonzalo Pizarro, Chang‐Fang Chiu, Michael Schenker, Aiwu Ruth He, Qi Wang, Caitlyn Stromko, Joseph Hreiki, Thomas Yau

Article2025

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Thomas Yau, Peter R. Galle, Thomas Decaens, Bruno Sangro, Shukui Qin, Leonardo Gomes da Fonseca, Hatim Karachiwala, Jean–Frédéric Blanc, Joong‐Won Park, Edward Gane, Matthias Pinter, Ana Matilla Peña, Masafumi Ikeda, David Tai, Armando Santoro, Gonzalo Pizarro, Chang‐Fang Chiu, Michael Schenker, Aiwu Ruth He, Hong Jae Chon, Joanna Wójcik-Tomaszewska, Gontran Verset,

Article2025

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses.

Masatoshi Kudo, Thomas Yau, Thomas Decaens, Bruno Sangro, Shukui Qin, Leonardo Gomes da Fonseca, Hatim Karachiwala, Joong‐Won Park, Edward Gane, Matthias Pinter, David Tai, Armando Santoro, Gonzalo Pizarro, Chang‐Fang Chiu, Michael Schenker, Aiwu Ruth He, Nan Hu, Maria Jesus Jimenez Exposito, Caitlyn Stromko, Peter R. Galle

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Discussion(0)

Related publications

Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses.